CROSS-REACTIVE DISPLACING ANTIBODIES FROM COLLAGEN-BINDING PROTEINS AND METHOD OF IDENTIFICATION AND USE
    1.
    发明申请
    CROSS-REACTIVE DISPLACING ANTIBODIES FROM COLLAGEN-BINDING PROTEINS AND METHOD OF IDENTIFICATION AND USE 有权
    来自胶原蛋白结合蛋白的交叉反应位移抗体及其鉴定和使用方法

    公开(公告)号:US20070122416A1

    公开(公告)日:2007-05-31

    申请号:US09810428

    申请日:2001-03-19

    摘要: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species. Antibodies generated in this manner have also been shown to exhibit displacement activity and can thus be utilized advantageously in methods wherein these antibodies will be administered to patients having pre-existing staphylococcal infections because of the ability to displace bacterial proteins from binding sites on the extracellular matrix. Finally, a method of identifying, isolating and utilizing displacing antibodies is also provided.

    摘要翻译: 提供了对CNA蛋白和来自胶原结合结构域的其他区域(包括结构域CNA19)的抗体,并且以这种方式产生的抗体已显示与金黄色葡萄球菌和表皮葡萄球菌交叉反应,因此可以用于 预防和治疗由这两种细菌引起的感染。 此外,可以使用本发明的抗体治疗医疗器械,以便减少或消除它们被感染或进一步扩散感染的可能性。 特别地,蛋白质是有利的,因为它们是交叉反应性的,并且因此可以施用于患者,以便减少或预防多于一种物种的葡萄球菌细菌的严重感染。 以这种方式产生的抗体也已显示出显示置换活性,因此可有利地用于其中将这些抗体施用于具有预先存在的葡萄球菌感染的患者的方法,因为能够从细胞外基质上的结合位点置换细菌蛋白质 。 最后,还提供了鉴定,分离和利用置换抗体的方法。

    Fibronectin binding protein compositions and methods of use
    3.
    发明申请
    Fibronectin binding protein compositions and methods of use 有权
    纤连蛋白结合蛋白组合物和使用方法

    公开(公告)号:US20070110748A1

    公开(公告)日:2007-05-17

    申请号:US11589760

    申请日:2006-10-31

    IPC分类号: A61K39/395 C07K16/18

    摘要: Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.

    摘要翻译: 公开了阻断纤连蛋白与纤连蛋白结合的抗体。 还公开了衍生自金黄色葡萄球菌的fnbA和fnbB基因的位点特异性突变和截短的肽表位,失语链球菌的fnbA和fnbB基因,以及化脓性链球菌的sfb基因,以及编码这些肽和表位的核酸片段。 产生阻断纤连蛋白结合蛋白与纤连蛋白结合的抗体的抗(纤连蛋白结合位点)抗体,肽和表位,以及编码这些蛋白质的DNA片段,并且可用于各种筛选,诊断和治疗应用,包括活性和 被动免疫和预防动物或人类中链球菌和葡萄球菌定居的方法。 这些。 提出DNA段及其衍生的肽直接用于疫苗的制备,也可用作疫苗制剂中的载体蛋白。

    Extracellular matrix-binding proteins from Staphylococcus aureus
    6.
    发明申请
    Extracellular matrix-binding proteins from Staphylococcus aureus 审中-公开
    来自金黄色葡萄球菌的细胞外基质结合蛋白

    公开(公告)号:US20050026170A1

    公开(公告)日:2005-02-03

    申请号:US10744616

    申请日:2003-12-24

    摘要: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD.

    摘要翻译: 描述了分离的细胞外基质结合蛋白,命名为ClfB,SdrC,SdrD和SdrE,以及它们相应的氨基酸和核酸序列和基序。 蛋白质,肽,其片段或其抗原部分可用于预防,抑制,治疗和诊断金黄色葡萄球菌感染以及科学研究工具。 此外,蛋白质,肽,其片段或其抗原部分的抗体或抗体片段也可用于预防,抑制,治疗和诊断金黄色葡萄球菌感染。 特别地,其蛋白质或其抗体可以施用于伤口或用于涂覆生物材料以用作阻断剂以预防或抑制金黄色葡萄球菌与伤口或生物材料的结合。 ClfB是具有约88kDa的预测分子量和约124kDa的表观分子量的细胞壁相关蛋白,其结合可溶性和固定的纤维蛋白原。 ClfB结合纤维蛋白原的α链和β链,并作为聚集因子。 SdrC,SdrD和SdrE是表现出阳离子依赖性配体结合细胞外基质的细胞壁相关蛋白。 已经发现,在SdrC,SdrD,SdrE,ClfA和ClfB的A区域中,存在可用于得到TYTFTDYVD的共有基序的高度保守的氨基酸序列。

    Staphylococcal immunotherapeutics via donor selection and donor stimulation
    7.
    发明申请
    Staphylococcal immunotherapeutics via donor selection and donor stimulation 审中-公开
    葡萄球菌免疫治疗通过供体选择和供体刺激

    公开(公告)号:US20060222651A1

    公开(公告)日:2006-10-05

    申请号:US11374065

    申请日:2006-03-14

    IPC分类号: A61K39/40 C07K16/12

    摘要: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.

    摘要翻译: 提供了感染或易感染葡萄球菌如金黄色葡萄球菌和表皮葡萄球菌感染的患者的被动免疫的方法和组合物,其包括选择或制备具有高抗体滴度的供体血浆池以精心选择的葡萄球菌 粘附素或MSCRAMM,或其片段或组分,或与其基本上同源的序列。 供体血浆池可以通过将具有高于正常滴度的抗体的单个血液或血液成分样品与一种或多种所选择的粘附素或与细胞外基质蛋白结合的其它蛋白质组合,或通过将精心挑选的蛋白质或肽施用于 诱导所需抗体表达的宿主,随后从被处理的宿主中回收增强的高效价血清或血浆池。